Saroglitazar, A Dual PPAR α/γ Agonist, Improves Atherogenic Dyslipidemia in Patients with Non-Cirrhotic Nonalcoholic Fatty Liver Disease: A Pooled Analysis.

Mohammad Shadab Siddiqui,Deven Parmar,Farheen Sheikh,Shiv Kumar Sarin,Laura Cisneros,Samer Gawrieh,Taufik Momin,Ajay Duseja,Arun J. Sanyal

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association（2023）

引用 4|浏览8

暂无评分

摘要

Saroglitazar improved the serum atherogenic lipoprotein profile in patients with NAFLD, irrespective of co-morbid conditions and statin use. Saroglitazar has the potential to not only positively affect liver disease but also reduce cardiovascular risk in patients with NAFLD.

查看译文

关键词

Nonalcoholic steatohepatitis,cardiovascular disease,lipids,saroglitazar,small dense LDL

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要